Hims & Hers Health, Inc. (NASDAQ: HIMS) skyrocketed nearly 16% on Tuesday, catching the attention of investors. This rally was sparked by news that the telehealth company successfully raised $1 billion in its largest funding round to date—a bold move that signals major growth ambitions and investor confidence.
So far in 2025, the stock has been nothing short of a rocket ship, surging over 150% year-to-date. Currently trading around $60.50, HIMS is sitting well above its 52-week low of $13.47, though still below its 52-week high of $72.98. With momentum building and strong financials backing the story, the question is clear: Could HIMS be on its way to setting a new all-time high this May?
Hims & Hers Health Inc. (HIMS)
What’s Fueling the Momentum?
-
Massive Capital Injection: The recent $1 billion funding round could provide significant firepower for product development, geographic expansion, or even strategic acquisitions.
-
Telehealth Tailwinds: The digital health space continues to grow rapidly, and Hims & Hers is well-positioned with a direct-to-consumer model that resonates with younger, tech-savvy consumers.
-
Strong Financials: Despite being a growth company, HIMS has shown strong revenue and controlled costs.
-
Brand Loyalty & Expansion: With a rapidly growing customer base and expanding service lines (mental health, skincare, hair loss, sexual health), the company is becoming a lifestyle health brand, not just a one-off prescription provider.
Why I’m Holding Back?
As much as the hype is real, not every investor is jumping in just yet. While the fundamentals look strong, some traders (myself included) are staying on the sidelines for now. Here's why:
-
Entry Price Challenges: With the stock already up over 150% this year, it's difficult to find a "safe" entry point without feeling like you're chasing the rally.
-
No Dividends: For income investors, HIMS offers no dividend—this is a pure growth play.
-
Valuation Concerns: Even with strong revenue growth, valuations can get stretched in a parabolic move. The risk of a pullback looms large for latecomers.
-
Patience Over FOMO: Chasing momentum can be risky. I’d rather wait for a technical pullback or some consolidation before considering an entry. Missing a bit of upside is better than buying into a potential top.
Final Thoughts
Hims & Hers has carved out a unique niche in the booming digital health space, and its recent funding round only strengthens its long-term outlook. But with the stock price already so high, timing a good entry point becomes more of a psychological game than a fundamental one. For now, I’m staying disciplined, avoiding the FOMO, and keeping this stock on my radar for a better opportunity.
Is HIMS the future of healthcare? Maybe. Right moment to jump in? Not for me—at least not yet.
Comments